Crossover designs have received great attention in clinical trials, as they allow subjects to serve as their own controls and gain such advantage as higher efficiency and smaller sample size over parallel designs, because the within-subject variability is in general smaller than between-subject variability. Response-adaptive crossover designs allow clinical trials to adapt and respond to the information acquired during the trials to achieve various objectives. Adaptive designs have been considered to allocate more subjects to superior treatments, improve statistical efficiency, reduce the sample size for cost savings, increase the sample size to maintain prespecified statistical power, or include auxiliary information. We focus on an adaptive allocation scheme to maximize the benefits from superior treatments, while maintaining a sufficiently high level of statistical efficiency, controlled by a suitable weight parameter. We review and discuss the strategy of incorporating multiple objectives, while advocating a regression type estimation approach via the Generalized Estimating Equations method. We show that the multiple objectives can be successfully incorporated to construct a spectrum of designs, ranging over various efficiencies and trial outcomes of success. Moreover, the adaptive allocation scheme successfully constructs designs with a desired efficiency, as illustrated by practical two- and three-period designs.
Part of the book: Recent Advances in Medical Statistics
Precision medicine typically refers to the use of genomic signatures of patients to assign more effective therapies to treat patients, or, for improved diagnosis of the early onset of a disease so that interventions can be delivered to prevent or delay the disease progression. Because the aim is to provide individualized patient treatment, such single-person trials are called N-of-1 trials. This chapter reviews fundamental ideas, models, and construction of optimal designs for N-of-1 trials, which are invariably constructed from crossover trials, where each patient receives a random sequence of trial treatments over time. We construct examples of universally optimal N-of-1 designs for comparing two treatments under various correlation structure assumptions and discuss how N-of-1 trials may be combined to form optimal aggregated N-of-1 trials for assessing average treatment effects for two or more treatments.
Part of the book: Recent Advances in Medical Statistics